StockData
Outlook Therapeutics, Inc. logo

Outlook Therapeutics, Inc. (OTLK) stock

OTLKNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 18, 2026Score 4/30
$0.36−0.04 (-8.94%)

Close on Nov 17, 2026Market cap $87.79MP/E –Yield –

Outlook Therapeutics total assets

Total assets on the balance sheet at the end of each period.

Outlook Therapeutics's total assets was $26.18M at Jun 30, 2026. For fiscal 2025 it was $18.58M, down 35.5% from the year before. Over ten years it grew -6.1% a year on average. The highest annual figure on record is $35.01M in fiscal 2015.

Annual total assets

PeriodPeriod endValueChange
FY2025Sep 30, 2025$18.58M-35.5%
FY2024Sep 30, 2024$28.82M-10.8%
FY2023Sep 30, 2023$32.30M+13.2%
FY2022Sep 30, 2022$28.53M+25.1%
FY2021Sep 30, 2021$22.81M+15.6%
FY2020Sep 30, 2020$19.73M+15.2%
FY2019Sep 30, 2019$17.13M-23.1%
FY2018Sep 30, 2018$22.28M+7.5%
FY2017Sep 30, 2017$20.73M-18.4%
FY2016Sep 30, 2016$25.41M-27.4%
FY2015Sep 30, 2015$35.01M–

Quarterly total assets

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q3 FY2026CQ2 2026Jun 30, 2026$26.18M+16.9%
Q2 FY2026CQ1 2026Mar 31, 2026$21.89M+14.8%
Q1 FY2026CQ4 2025Dec 31, 2025$18.24M+7.2%
Q4 FY2025CQ3 2025Sep 30, 2025$18.58M-35.5%
Q3 FY2025CQ2 2025Jun 30, 2025$22.39M-52.5%
Q2 FY2025CQ1 2025Mar 31, 2025$19.08M-67.7%
Q1 FY2025CQ4 2024Dec 31, 2024$17.01M-21.6%
Q4 FY2024CQ3 2024Sep 30, 2024$28.82M-10.8%
Q3 FY2024CQ2 2024Jun 30, 2024$47.09M+5.9%
Q2 FY2024CQ1 2024Mar 31, 2024$59.03M+9.3%
Q1 FY2024CQ4 2023Dec 31, 2023$21.68M-65.4%
Q4 FY2023CQ3 2023Sep 30, 2023$32.30M+13.2%
Q3 FY2023CQ2 2023Jun 30, 2023$44.45M+15.2%
Q2 FY2023CQ1 2023Mar 31, 2023$54.02M-31.3%
Q1 FY2023CQ4 2022Dec 31, 2022$62.69M+174.8%
Q4 FY2022CQ3 2022Sep 30, 2022$28.53M-13.2%
Q3 FY2022CQ2 2022Jun 30, 2022$38.59M+208.3%
Q1 FY2022CQ4 2021Dec 31, 2021$78.68M+298.7%
Q4 FY2021CQ3 2021Sep 30, 2021$22.81M-24.6%
Q3 FY2021CQ2 2021Jun 30, 2021$32.88M+149.7%
Q1 FY2021CQ4 2020Dec 31, 2020$12.52M+20.1%
Q4 FY2020CQ3 2020Sep 30, 2020$19.73M+15.2%
Q3 FY2020CQ2 2020Jun 30, 2020$30.24M-8.9%
Q2 FY2020CQ1 2020Mar 31, 2020$13.17M-23.3%
Q1 FY2020CQ4 2019Dec 31, 2019$10.42M-44.3%
Q4 FY2019CQ3 2019Sep 30, 2019$17.13M-23.1%
Q3 FY2019CQ2 2019Jun 30, 2019$33.21M-2.6%
Q2 FY2019CQ1 2019Mar 31, 2019$17.17M-38.2%
Q1 FY2019CQ4 2018Dec 31, 2018$18.71M-42.0%
Q4 FY2018CQ3 2018Sep 30, 2018$22.28M+7.5%
Q3 FY2018CQ2 2018Jun 30, 2018$34.09M+99.0%
Q2 FY2018CQ1 2018Mar 31, 2018$27.79M+59.1%
Q1 FY2018CQ4 2017Dec 31, 2017$32.28M+57.9%
Q4 FY2017CQ3 2017Sep 30, 2017$20.73M-18.4%
Q3 FY2017CQ2 2017Jun 30, 2017$17.13M-48.1%
Q2 FY2017CQ1 2017Mar 31, 2017$17.46M-29.7%
Q1 FY2017CQ4 2016Dec 31, 2016$20.45M–
Q4 FY2016CQ3 2016Sep 30, 2016$25.41M–
Q3 FY2016CQ2 2016Jun 30, 2016$32.99M–
Q2 FY2016CQ1 2016Mar 31, 2016$24.83M–

More Outlook Therapeutics figures

See a number that looks wrong?